DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This two-part study will include a dose escalation part to determine the recommended dose for
expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy,
safety, and tolerability of the combination.